Labcorp Holdings Inc. Q1 FY2026 earnings call

• Partner of choice with health systems and labs: Nationwide collaboration with Children's Hospital of Philadelphia, acquisition of Krause Health Laboratory Alliance assets, and deal with Parkview Health for outreach labs. - Specialty testing progress: Growth in oncology, women's health, neurology, etc., with specialty areas growing 2-3 times faster than broader market. LabCorp supported 85% of FDA-approved new drugs last year. - Consumer health: LabCorp OnDemand launched new tests, My LabCorp app launching in May with AI assistant. - Technology use: Collaboration with PathAI, AWS, Optimum AI to enhance customer experience and operational efficiency. Fortune named LabCorp most innovative for 4th year, and Ethisphere recognized as world's most ethical company.

Enterprise revenue reached $3.5 billion, up 6%. Diagnostics revenue increased 5% to $2.8 billion, with 2.9% organic growth, 2% acquisition-driven growth, and 0.2% from foreign currency translation. Biofarmer laboratory services revenue grew to $781 million, up 8.2% with 3.7% organic growth and 5.5% benefit from foreign currency translation. Diagnostics contributes approximately 80% of enterprise revenue, and biopharma laboratory services contributes around 22.3%.

• Enterprise revenue expected to grow 5%-6.1%. - Adjusted EPS guidance range $17.70-$18.35, midpoint raised by 13 cents. - Free cash flow guidance $1.24 billion-$1.36 billion, weighted towards second half. - Diagnostics segment revenue expected to grow 5.1%-5.9%, BLS segment 3.8%-5.4%.

• Weather impact: Approximately $15 million impact in Q1 on diagnostics, organic volume growth would be ~2% without weather. - ACA exchange: Potential 30 basis point volume impact, monitored for insured participants' testing utilization. - CRUSH initiative: CMS effort to reduce fraud, waste, abuse, need to avoid unintended consequences on patient access. - Fuel costs: Estimated $5-$10 million impact this year from dynamic oil prices, mitigated by hybrid vehicles. - Weather uncertainty: Difficult to project weather impact on forecast, but considered in revenue guidance range.

Q: Lisa Gill of JP Morgan asked about weather impact in Q1 and ACA exchange potential changes.

A: Weather had ~$15 million impact, organic volume growth would be ~2% without weather. ACA impact in Q1 was immaterial, but 30 basis point volume impact still expected.

Q: Jack Meehan of Nefron Research asked about CRUSH initiative.

A: Supportive of reducing fraud, waste, abuse, worked with ACLA and submitted comment letter.

Q: Michael Cherney of Learing Partners asked about DX volume and test per requisition.

A: Diagnostics revenue up 5%, organic growth ~3%, volume growth 2.5%, price mix up 2.6%.

Q: Patrick Donnelly of Citi asked about BLS booking trends.

A: BLS revenue up 8%, central labs driving growth, quarterly book-to-bill expected to improve sequentially.

Q: Tycho Peterson of Jefferies asked about esoteric testing and reimbursement.

A: Strong momentum in specialty areas, neurology and oncology growing, reimbursement to improve over time.

Q: Elizabeth Anderson of Evercore ISI asked about PAMA survey and Results Act.

A: Waiting for CBO score and CMS assessments, impact to LabCorp depends on other labs reporting data.

Q: David Westenberg of Piper Sandler asked about consumer testing and investments.

A: LabCorp OnDemand growing double digits, continue to invest in new products, focus on high margin specialty areas.

Q: Michael Riskin of Bank of America asked about Launchpad initiative and margins.

A: Launchpad on track, using tech to reduce costs and improve customer experience, margins improved in Q1.

Q: Luke Sergot of Barclays asked about fuel costs and weather recapture.

A: Minimal impact from fuel costs, weather impact on 20-25% of business recaptured over time, no explicit weather assumption in forecast.

Q: Erin Wright of Morgan Stanley asked about deal pipeline.

A: Pipeline remains strong, health systems looking for partnerships, expect more deals in future.